Orna Therapeutics showcased groundbreaking data at ASH 2024, highlighting its panCAR™ platform's effectiveness in delivering RNA for B cell-mediated diseases, promising new treatment pathways.

Eli Lilly has announced its acquisition of Orna Therapeutics, aiming to innovate cell therapies with advanced RNA technology. This strategic move will enhance its capabilities in genetic medicine.

Orna Therapeutics shared compelling in vivo CAR program data targeting autoimmune diseases at the ASH Annual Meeting. Learn more about their innovative therapies.

Orna Therapeutics announces significant presentations on its in vivo CAR therapies targeting autoimmune diseases at the upcoming ASH Annual Meeting in Orlando.

Orna Therapeutics will highlight its innovative in vivo CAR therapy approach for autoimmune diseases at the upcoming ACR Annual Meeting in Chicago.

Orna Therapeutics has revealed groundbreaking preclinical data at the ASGCT Annual Meeting, showcasing its innovative in vivo CAR therapy aimed at autoimmune diseases, highlighting potent findings that could transform treatment.

Orna Therapeutics is set to present its cutting-edge in vivo CAR therapy for autoimmune conditions at the prestigious ASGCT Annual Meeting, exhibiting its groundbreaking approach in gene therapy.

Orna Therapeutics has appointed Joseph Bolen, Ph.D. as CEO to guide the company in its clinical trials for innovative RNA therapies targeting cancer and autoimmune diseases.

Orna Therapeutics and Simnova expand their collaboration, focusing on BCMA-targeted RNA therapeutics, enhancing treatment options for multiple myeloma patients.

Orna Therapeutics enhances its board with the addition of Vikas Sinha, a finance expert, to drive growth in RNA medicine development.